SLC13A4

Across TCGA pan-cancer cohorts, SLC13A4 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SLC13A4 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher SLC13A4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC13A4 expression acts as an unfavorable survival marker.

MESO, ESCA, and LIHC are the cancer types where SLC13A4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	All	0.096	0.369	.007	18	view →
ESCA	OS	Median	All	0.095	0.701	<.001	12	view →
LIHC	DFS	Median	All	0.120	0.561	<.001	12	view →
COAD	DFS	Median	II,III,IV	0.200	0.648	.019	9	view →
READ	OS	Median	II,III,IV	0.187	0.653	.030	6	view →
HNSC	OS	Median	All	0.187	0.685	.039	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SLC13A4–MESO (DFS)

Open the MESO breakdown →